Heparin Beyond Anticoagulation in Sepsis – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Patricia C Liaw et al, adding:
“The evolving role of heparin in sepsis: therapeutic potential in the age of immunothrombosis
Sepsis is marked by immunothrombosis, where inflammation, coagulation, endothelial injury, platelet activation, and NET formation drive both large and small vessel occlusion.
Heparin has re-emerged as a candidate because its actions reach beyond anticoagulation to anti-inflammatory, antimicrobial, and NET-modulating effects.
Trial evidence is limited, and COVID-19 data hint at benefit early and possible harm in advanced disease.”
Title: The evolving role of heparin in sepsis: therapeutic potential in the age of immunothrombosis
Authors: Patricia C Liaw, Ryan Zarychanski, Patrick R Lawler, Sylvain A Lother, Asher A Mendelson
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 10, 2026, 16:28Can the VWF to ADAMTS-13 Ratio Predict Mortality in Sepsis-Induced Coagulopathy? – RPTH Journal
-
Nov 10, 2026, 16:28Ruth Willems: PhD Defence at Maastricht University on Thrombosis and Bleeding in HPB Disease
-
Nov 10, 2026, 16:09Edward Lee Carter: Factor XIa Inhibition Enters Clinical Practice
-
Nov 10, 2026, 16:08Edward C.C. Wong: Deriving Ferritin Cutoffs for Iron Deficiency Using RBC Parameters
-
Nov 10, 2026, 16:07Milad Abdalla: Decoding Hemoglobin Electrophoresis – A Practical Diagnostic Reference
-
Nov 10, 2026, 15:13Wolfgang Miesbach: Nonviral Gene Therapy for Haemophilia A Using Lipid Nanoparticles
-
Nov 10, 2026, 15:06Dahra Teles: First Speaking Experience at HEMO 2026 on First-Line Multiple Myeloma Treatment
-
Nov 10, 2026, 14:55Yazan Abou-Ismail: First FDA-Approved Factor XIa Inhibitor for Stroke Prevention
-
Nov 10, 2026, 14:49Ifeanyichukwu Ifechidere: The Role of Coagulation in Anaesthesia and Surgery